Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Descrizione del progetto

La biostampa dei tumori: il futuro della scoperta di farmaci

Gli attuali approcci per lo studio della biologia dei tumori e per lo svolgimento dello screening farmacologico si affidano alle colture cellulari bidimensionali e ai modelli animali. Tali soluzioni, tuttavia, non rispecchiano accuratamente le dimensioni, l’eterogeneità e la vascolarità del microambiente che caratterizza i tumori umani. Gli scienziati del progetto TUMOURPRINT, finanziato dall’UE, stanno lavorando a una dirompente tecnologia di biostampa in grado di fabbricare modelli di tessuti ad alta fedeltà. Questa tecnologia si avvale di cellule vive combinate con idrogel appositamente formulati che forniscono alle cellule un ambiente ottimale per la sopravvivenza, la crescita e uno sviluppo tridimensionale adeguato. Si prevede che i risultati rivoluzioneranno i processi di sviluppo dei farmaci offrendo modelli tumorali in modo preciso, automatizzato e riproducibile.

Obiettivo

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform.
TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-EIC-SMEInst-2018-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

BICO GROUP AB
Contributo netto dell'UE
€ 2 450 327,25
Indirizzo
ARVID WALLGRENS BACKE 20
413 46 Goteborg
Svezia
PMI
Sì
Regione
Södra Sverige Västsverige Västra Götalands län
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 3 500 467,50